Related Stories
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3319
[post_author] => 3
[post_date] => 2019-08-13 15:43:10
[post_date_gmt] => 2019-08-13 15:43:10
[post_content] => The newly re-authorized Commercialization Readiness Pilot (CRP) program is now accepting applications from previously or currently HHS-funded SBIR and STTR Phase II and Phase IIB awardees.
NHLBI open and accepting applications from NHLBI grantees for the September 5th NIH SBIR/STTR receipt date; HHS/NIH general applications will be accepted from August 5, 2019 until April 6, 2022 via standard due dates.
CPR can provide over $3 million in additional funding to facilitate the commercialization transition for projects, and support work that is not typically supported through SBIR/STTR Phase II or Phase IIB awards, including:
- Preparation of documents for a Food and Drug Administration (FDA) submission
- Development of an intellectual property strategy
- Investigational New Drug (IND)-enabling studies
- Clinical studies
- Manufacturing costs
- Regulatory assistance
- Subcontracted work to other institutions, including contract research organizations (CRO)
- A combination of services.
Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award. Please note, this re-authorization includes (3) separate Funding Opportunity Announcements (FOAs) with varying participating NIH Institutes and Centers. Learn more here: https://sbir.nih.gov/funding#crp
[post_title] => SBIR/STTR Commercialization Readiness Pilot (CRP) Program Deadlines
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => sbirsttr-commercialization-readiness-pilot-crp-program-deadlines
[to_ping] =>
[pinged] =>
[post_modified] => 2019-08-13 15:43:10
[post_modified_gmt] => 2019-08-13 15:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3319
[menu_order] => 89
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3266
[post_author] => 3
[post_date] => 2019-05-21 18:27:06
[post_date_gmt] => 2019-05-21 18:27:06
[post_content] => Two important updates regarding upcoming BARDA DRIVe funding opportunities:
Drive Special Instructions – Due May 28!
White papers, quad chart, and application form for the DRIVe special instructions to the BARDA BAA are due by 3:00 PM ET on Tuesday May 28th, 2019.
Focus areas are:
• 15.1: Advanced Research and Development of Sepsis Diagnostics and Devices
• 15.2: Post-sepsis Monitoring
• 16.1: On-Person, Wearable, and Biosensing Devices (Host Response and Direct Pathogen Detection)
Steps to apply:
1.Review Solicitation BAA-18-100-SOL-00003 on fbo.gov.
2.Schedule a meeting with the ENACT or Solving Sepsis team (strongly encouraged).
3.Download the DRIVe Special Instructions Submission Form.*
4.Complete the PDF form, Quad Chart, White Paper, and Addendum (ROM cost estimate).
5. Email your submission to DRIVeContracting@hhs.gov by 3:00PM ET on May 28th.
6. You will receive an email notification confirming receipt within 5 business days. DRIVe personnel will review your white paper as described in the solicitation.
7. DRIVe personnel will notify you of the outcome of that review and may invite you to submit a full proposal.
*You must download the PDF, as filling it out in a browser window will disable some key functionality.
General DRIVe EZ-BAA - Deadline Extended
The deadline for DRIVe’s EZ-BAA has been extended to 3:00 PM ET on November 15th, 2019. Applications are reviewed on a rolling basis with a response as early as 30 days after submission.
DRIVe has a new online portal for submitting EZ-BAA. Note: Companies must register for a profile in the online portal here, it can take up to 1 business day to account to be created.
[post_title] => DRIVe Special Instructions & EZ-BAA Updates
[post_excerpt] => DRIVe special instructions to the BARDA BAA are due by 3:00 PM ET on Tuesday May 28th! General application deadline for EZ-BAA extended until November 15th.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => drive-special-instructions-ez-baa-updates
[to_ping] =>
[pinged] =>
[post_modified] => 2019-05-21 18:27:06
[post_modified_gmt] => 2019-05-21 18:27:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3266
[menu_order] => 95
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2064
[post_author] => 3
[post_date] => 2015-12-07 20:15:00
[post_date_gmt] => 2015-12-07 20:15:00
[post_content] => Accelerating Biomedical Discoveries for Commercialization
STONY BROOK, N.Y. – December 7, 2015 - The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.
The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards.
Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology. Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization.
The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are:
Feasibility awards
- Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors - Dr. Carol Carter
- Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer - Dr. Michael Frohman
- Novel miR-129 Based Therapeutics for Colon Cancer - Dr. Jingfang Ju
- Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes - Dr. Dima Kosakov
- Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs - Dr. Gabriel Pagnotti
- Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration - Dr. Yixian Qin
- LDL as Biomarker for Childhood Tuberculosis (TB) - Dr. Xinxin Yang
- A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology - Dr. Marcous Abboud
- Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams - Dr. Avraham Dilmanian
- NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) - Dr. Amirhossein Goldan
- Azasteroids for Combination Anti-TB Therapy - Dr. Nicole Sampson
- A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre - Dr. Eckard Wimmer
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )